Our Approach
A smarter way to combine cancer therapies
While immunotherapies have transformed cancer care, their side effects and limited tolerability often prevent patients from receiving the best possible outcomes.
VINCOBODIES are our answer: small, modular medicines designed to deliver the strength of combination treatment with fewer trade-offs.
Image adapted from Yang EY, Shah K. Front Oncol 2020. doi: 10.3389/fonc.2020.01182. Licensed under CC BY.
What makes VINCOBODIES different
Combination power in one medicine: engage two or more targets at once or carry multiple cancer-fighting payloads, without stacking multiple drugs
Built to be gentler: a design that aims for fewer serious side effects so patients can stay on treatment
Reaches tumors more effectively: a compact format to penetrate tumors at low doses
Simple dosing: designed for convenient, under-the-skin dosing
Why this matters
Our approach enables safer use of powerful combinations including targets like PD-1 + CTLA-4 that are often limited by toxicity today and opens the door to multi-payload antibody drug conjugates (ADCs) for hard-to-treat cancers.
The platform lets us adapt quickly as new data emerge, adding or swapping targets or payloads without starting from scratch.
Designed for real-world use
Stable, manufacturable, and built to move promising programs into the clinic efficiently
